A. Nash

发表

Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.

J. Nelson, S. Wilkinson, Jaskaran Singh, 2021, The Journal of clinical psychiatry.

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

T. P. Lebold, P. Bonaventure, W. Drevets, 2020, Translational Psychiatry.

Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform

A. Dibernardo, S. Borentain, A. Nash, 2020, BMC Psychiatry.

Understanding healthcare burden and treatment patterns among young adults with schizophrenia

Li Wang, K. Joshi, T. Amos, 2018, Journal of medical economics.

A Choice-Based Conjoint Analysis of the Psychiatrist Decision-Making Process Used in Determining When to Discharge Adults With Major Depressive Disorder Hospitalized for Active Suicidal Ideation With Intent

S. Wilkinson, J. Sheehan, C. Neslusan, 2021, The Journal of nervous and mental disease.

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior

D. Ionescu, I. Turkoz, R. Lane, 2021, Journal of clinical psychopharmacology.

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA

C. Neslusan, P. Lefebvre, K. Joshi, 2021, PharmacoEconomics.

Commonly Used Therapeutics Associated with Changes in Arousal Inhibit GABAAR Activation

A. Jenkins, D. Rye, L. Trotti, 2023, Biomolecules.

Factors Affecting Noncompliance With Buprenorphine Maintenance Treatment

Bethany Ketchen, Pamela Eilender, Ayman Fareed, 2014, Journal of addiction medicine.

Characteristics and current standard of care among veterans with major depressive disorder in the United States: A real-world data analysis.

J. Sheehan, K. Joshi, A. Near, 2022, Journal of affective disorders.

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

M. Mathews, A. Savitz, Edward Kim, 2019, Neuropsychiatric disease and treatment.

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

M. Mathews, Qiaoyi Zhang, Shien Guo, 2023, BMC Psychiatry.

Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.

P. Lefebvre, K. Joshi, D. Pilon, 2022, Clinical therapeutics.